{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T22:52:42Z","timestamp":1792363962889,"version":"4.4.0"},"reference-count":41,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["SJU"],"abstract":"<jats:p>Objective: This study aimed to describe the regional, population-based, organised prostate cancer testing (OPT) programmes that are being introduced throughout Sweden: motives, structure, target population, diagnostic algorithm, quality control, outcomes, research, and future perspectives.\nResults: In 2018, the Swedish National Board of Health and Welfare renewed their recommendation against screening for prostate cancer. Despite this, regional OPT was considered motivated to (1) improve cost-effectiveness compared with unorganised testing, (2) improve equity by giving every man in the target population a chance to make an informed choice, and (3) gain diagnostic and organisational knowledge. The OPT programmes are provided as a regional public healthcare service. They are coordinated by a national working group. The final target population is all men aged 50\u201374 years. Regional OPT offices use a national administrative system to organise all steps from sending invitation letters to prostate biopsy according to a strict diagnostic algorithm. General practice is involved for blood draw only or not at all. Data are registered in a national register (SweOPT); an annual report is published with the regions\u2019 performance on key indicators. At the end of 2024, 16 of the 21 Swedish regions had started OPT and invited 256,000 men with an average cumulative participation rate of 43%. A consortium co-ordinates OPT-related research. A general experience is that communication and organisational matters have been more challenging than medical decisions.\nConclusions: The Swedish population-based OPT programmes provide organisational experiences, diagnostic outcomes, and research results of value for future national prostate cancer screening programmes.<\/jats:p>","DOI":"10.2340\/sju.v60.43809","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T04:31:02Z","timestamp":1748925062000},"page":"97-104","source":"Crossref","is-referenced-by-count":22,"title":["Swedish regional population-based organised prostate cancer testing: why, what and how?"],"prefix":"10.2340","volume":"60","author":[{"given":"Ola","family":"Bratt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salma Tun\u00e5","family":"Butt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Carlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Jelf-Eneqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olof","family":"Gunnarsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alma","family":"Ihre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Jiborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Lantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heide","family":"Larsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Str\u00f6mqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Styrke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils-Erik","family":"Svedberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecka","family":"Arnsrud Godtman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2025,6,3]]},"reference":[{"key":"113622","doi-asserted-by":"crossref","unstructured":"Bergengren O, Pekala KR, Matsoukas K, et al. 2022 Update on prostate cancer epidemiology and risk factors \u2013 a systematic review. Eur Urol. 2023;84:191\u2013206. https:\/\/doi.org\/10.1016\/j.eururo.2023.04.021","DOI":"10.1016\/j.eururo.2023.04.021"},{"key":"113623","doi-asserted-by":"crossref","unstructured":"Hugosson J, Roobol MJ, M\u00e5nsson M, et al. A 16-yr follow-up of the European randomized study of screening for prostate cancer. Eur Urol. 2019;76:43\u201351. https:\/\/doi.org\/10.1016\/j.eururo.2019.02.009","DOI":"10.1016\/j.eururo.2019.02.009"},{"key":"113624","doi-asserted-by":"crossref","unstructured":"Nelson HD, Fu R, Cantor A, et al. Effectiveness of breast cancer screening: systematic review and meta-analysis to update the 2009 U.S. Preventive Services Task Force Recommendation. Ann Intern Med. 2016;164:244\u2013255. https:\/\/doi.org\/10.7326\/M15-0969","DOI":"10.7326\/M15-0969"},{"key":"113625","doi-asserted-by":"crossref","unstructured":"Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 2010;11:725\u2013732. https:\/\/doi.org\/10.1016\/S1470-2045(10)70146-7","DOI":"10.1016\/S1470-2045(10)70146-7"},{"key":"113626","doi-asserted-by":"crossref","unstructured":"Bratt O, Auvinen A, Arnsrud Godtman R, et al. Screening for prostate cancer: evidence, ongoing trials, policies and knowledge gaps. BMJ Oncol. 2023;2(e000039):1\u201313. https:\/\/doi.org\/10.1136\/bmjonc-2023-000039","DOI":"10.1136\/bmjonc-2023-000039"},{"key":"113627","doi-asserted-by":"crossref","unstructured":"Rai B, Nordstr\u00f6m T, Lantz A, et al. Spatio-temporal variation in prostate cancer testing in Stockholm: a population-based study. PLoS One. 2024;19:e0308254. https:\/\/doi.org\/10.1371\/journal.pone.0308254","DOI":"10.1371\/journal.pone.0308254"},{"key":"113628","doi-asserted-by":"crossref","unstructured":"Arnsrud Godtman R, Holmberg E, Lilja H, et al. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Goteborg randomized population-based prostate cancer screening trial. Eur Urol. 2015;68:354\u2013360. https:\/\/doi.org\/10.1016\/j.eururo.2014.12.006","DOI":"10.1016\/j.eururo.2014.12.006"},{"key":"113629","doi-asserted-by":"crossref","unstructured":"Alterbeck M, Jarbur E, Thimansson E, et al. Designing and implementing a population-based organised Prostate Cancer Testing Pro-gramme. Eur Urol Focus. 2022;8:1568\u20131574. https:\/\/doi.org\/10.1016\/j.euf.2022.06.008","DOI":"10.1016\/j.euf.2022.06.008"},{"key":"113630","doi-asserted-by":"crossref","unstructured":"Fazekas T, Shim SR, Basile G, et al. Magnetic resonance imaging in prostate cancer screening: a systematic review and meta-analysis. JAMA Oncol. 2024;10:745\u2013754. https:\/\/doi.org\/10.1001\/jamaoncol.2024.0734","DOI":"10.1001\/jamaoncol.2024.0734"},{"key":"113631","doi-asserted-by":"crossref","unstructured":"Hugosson J, Godtman RA, Wallstr\u00f6m J, et al. Results after four years of screening for prostate cancer with PSA and MRI. N Engl J Med. 2024;391:1083\u20131095. https:\/\/doi.org\/10.1056\/NEJMoa2406050","DOI":"10.1056\/NEJMoa2406050"},{"key":"113632","doi-asserted-by":"crossref","unstructured":"Robinson D, Abdulkareem R, Nasrollah D, et al. Frequency of biopsy and tumor grade before vs after introduction of prostate magnetic resonance imaging. JAMA Netw Open. 2023;6:e2330233. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.30233","DOI":"10.1001\/jamanetworkopen.2023.30233"},{"key":"113633","unstructured":"European Union Council. Council recommendation of 9 December 2022 on strengthening prevention through early detection: a new EU approach on cancer screening replacing Council Recommendation 2003\/878\/EC. Offic J Eur Union. 2022;C 473\/1."},{"key":"113634","unstructured":"Organisation for Economic Co-operation and Development. EU country cancer profiles [Internet]. 2023. [cited 15th March 2025]Available from: https:\/\/www.oecd.org\/en\/publications\/eu-country-cancer-profiles_55f07000-en.html"},{"key":"113635","doi-asserted-by":"crossref","unstructured":"Thimansson E, Axen E, J\u00e4derling F, et al. A novel approach to integrated prostate cancer diagnostics: insights from MRI, prostate biopsy, and pathology reports in a pilot study. BJU Int. 2025;135:245\u2013248. https:\/\/doi.org\/10.1111\/bju.16582","DOI":"10.1111\/bju.16582"},{"key":"113636","doi-asserted-by":"crossref","unstructured":"Hofvind S, Iqbal N, Thy JE, et al. Effect of invitation letter in language of origin on screening attendance: randomised controlled trial in BreastScreen Norway. BMJ. 2023;382:e075465. https:\/\/doi.org\/10.1136\/bmj-2023-075465","DOI":"10.1136\/bmj-2023-075465"},{"key":"113637","doi-asserted-by":"crossref","unstructured":"Carlsson SV, Arnsrud Godtman R, Pihl CG, et al. Young age on starting prostate-specific antigen testing is associated with a greater reduc-tion in prostate cancer mortality: 24-year follow-up of the Goteborg randomized population-based prostate cancer screening trial. Eur Urol. 2023;83:103\u2013109. https:\/\/doi.org\/10.1016\/j.eururo.2022.10.006","DOI":"10.1016\/j.eururo.2022.10.006"},{"key":"113638","doi-asserted-by":"crossref","unstructured":"Alberts AR, Schoots IG, Bokhorst LP, et al. Characteristics of Prostate Cancer Found at Fifth Screening in the European Randomized Study of Screening for Prostate Cancer Rotterdam: Can We Selectively Detect High-grade Prostate Cancer with Upfront Multivariable Risk Stratification and Magnetic Resonance Imaging? Eur Urol. 2018;73:343-50. https:\/\/doi.org\/10.1016\/j.eururo.2017.06.019","DOI":"10.1016\/j.eururo.2017.06.019"},{"key":"113639","doi-asserted-by":"crossref","unstructured":"Bratt O, Carlsson S, Fransson P, et al. The Swedish national guidelines on prostate cancer, part 1: early detection, diagnostics, staging, patient support and primary management of non-metastatic disease. Scand J Urol. 2022;56:265\u2013273. https:\/\/doi.org\/10.1080\/21681805.2022.2094462","DOI":"10.1080\/21681805.2022.2094462"},{"key":"113640","doi-asserted-by":"crossref","unstructured":"Stranne J. 2023\/2024 update of the national prostate cancer guidelines in Sweden. Scand J Urol. 2024;59:210\u2013211. https:\/\/doi.org\/10.2340\/sju.v59.42656","DOI":"10.2340\/sju.v59.42656"},{"key":"113641","unstructured":"Confederation of Regional Cancer Centres. Organised prostate cancer testing (OPT): description and recommendations, Version 6.0 [Inter-net]. 2025. [cited 15th March 2025] Available from: https:\/\/cancercentrum.se\/samverkan\/vara-uppdrag\/prevention-och-tidig-upptackt\/prostatacancertestning\/"},{"key":"113642","doi-asserted-by":"crossref","unstructured":"Arsov C, Albers P, Herkommer K, et al. A randomized trial of risk-adapted screening for prostate cancer in young men-results of the first screening round of the PROBASE trial. Int J Cancer. 2022;150(11):1861\u20131869. https:\/\/doi.org\/10.1002\/ijc.33940","DOI":"10.1002\/ijc.33940"},{"key":"113643","doi-asserted-by":"crossref","unstructured":"Nordstr\u00f6m T, Annerstedt M, Glaessgen A, et al. Repeated prostate cancer screening using prostate-specific antigen testing and magnetic resonance imaging: a secondary analysis of the STHLM3-MRI randomized clinical trial. JAMA Netw Open. 2024;7:e2354577. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.54577","DOI":"10.1001\/jamanetworkopen.2023.54577"},{"key":"113644","doi-asserted-by":"crossref","unstructured":"Nordstr\u00f6m T, Discacciati A, Bergman M, et al. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial. Lancet Oncol. 2021;22:1240\u20131249. https:\/\/doi.org\/10.1016\/S1470-2045(21)00348-X","DOI":"10.1016\/S1470-2045(21)00348-X"},{"key":"113645","doi-asserted-by":"crossref","unstructured":"Alterbeck M, Thimansson E, Bengtsson J, et al. A pilot study of an organised population-based testing programme for prostate cancer. BJU Int. 2024;133:87\u201395. https:\/\/doi.org\/10.1111\/bju.16143","DOI":"10.1111\/bju.16143"},{"key":"113646","doi-asserted-by":"crossref","unstructured":"Albers P, van Poppel H. Prostate cancer screening at its best: the Swedish organized prostate cancer testing program. Eur Urol. 2024;85:215\u2013216. https:\/\/doi.org\/10.1016\/j.eururo.2023.11.026","DOI":"10.1016\/j.eururo.2023.11.026"},{"key":"113647","doi-asserted-by":"crossref","unstructured":"Bratt O, Godtman RA, Jiborn T, et al. Population-based organised prostate cancer testing: results from the first invitation of 50-year-old men. Eur Urol. 2024;85:207\u2013214. https:\/\/doi.org\/10.1016\/j.eururo.2023.11.013","DOI":"10.1016\/j.eururo.2023.11.013"},{"key":"113648","doi-asserted-by":"crossref","unstructured":"J\u00e4rbur E, Holmberg E, Bj\u00f6rk-Eriksson T, et al. Associations between socioeconomic factors and PSA testing in a population-based organised testing programme and routine healthcare: a register-based study of 50-year-old men. BMJ Oncol. 2024;3:1\u20137. https:\/\/doi.org\/10.1136\/bmjonc-2024-000400","DOI":"10.1136\/bmjonc-2024-000400"},{"key":"113649","doi-asserted-by":"crossref","unstructured":"J\u00e4rbur E, Arnsrud Godtman R, Bonander C, et al. Associations between neighbourhood characteristics and participation in a population-based organised prostate cancer testing (OPT) programme: a register-based study of 50-year-old men. PLoS One. 2025;20(4):e0322643. https:\/\/doi.org\/10.1371\/journal.pone.0322643","DOI":"10.1371\/journal.pone.0322643"},{"key":"113650","doi-asserted-by":"crossref","unstructured":"Helgestad ADL, Andersen B, Njor SH, Larsen MB. The association of demographic and socioeconomic variables with cancer screening partic-ipation: a national cross-sectional study of three cancer screening programs in Denmark. Heliyon. 2024;10:e31163. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e31163","DOI":"10.1016\/j.heliyon.2024.e31163"},{"key":"113651","doi-asserted-by":"crossref","unstructured":"Thimansson E, Zackrisson S, J\u00e4derling F, et al. A pilot study of AI-assisted reading of prostate MRI in organized prostate cancer testing. Acta Oncol. 2024;63:816\u2013821. https:\/\/doi.org\/10.2340\/1651-226X.2024.40475","DOI":"10.2340\/1651-226X.2024.40475"},{"key":"113652","doi-asserted-by":"crossref","unstructured":"Svensson L, Stinesen Bratt K, et al. Men\u2019s perception of being invited for prostate cancer testing and the information about its pros and cons \u2013 a survey from two population-based testing programmes. Eur Urol Open Sci. 2023;52:66\u201371. https:\/\/doi.org\/10.1016\/j.euros.2023.03.012","DOI":"10.1016\/j.euros.2023.03.012"},{"key":"113653","doi-asserted-by":"crossref","unstructured":"Arvendell M, Phillips L, Delilovic S, et al. Men\u2019s attitudes towards participation in organised prostate cancer testing: an abductive thematic analysis. Eur Urol Open Sci. 2025;71:156\u2013164. https:\/\/doi.org\/10.1016\/j.euros.2024.12.007","DOI":"10.1016\/j.euros.2024.12.007"},{"key":"113654","unstructured":"Svensson L, Bratt O, Hugosson J, Stinesen K. Prostate cancer screening decisions: which aspects do men value most? An interview study with men invited to a population-based program. Am J Mens Health. 2025."},{"key":"113655","doi-asserted-by":"crossref","unstructured":"Hao S, Discacciati A, Eklund M, et al. Cost-effectiveness of prostate cancer screening using magnetic resonance imaging or standard biopsy based on the STHLM3-MRI study. JAMA Oncol. 2022;9(1):88\u201394. https:\/\/doi.org\/10.1001\/jamaoncol.2022.5252","DOI":"10.1001\/jamaoncol.2022.5252"},{"key":"113656","doi-asserted-by":"crossref","unstructured":"Van Poppel H, Roobol MJ, Chandran A. Early detection of prostate cancer in the European Union: combining forces with PRAISE-U. Eur Urol. 2023;84:519\u2013522. https:\/\/doi.org\/10.1016\/j.eururo.2023.08.002","DOI":"10.1016\/j.eururo.2023.08.002"},{"key":"113657","doi-asserted-by":"crossref","unstructured":"Bratt O. The long and winding road from guideline recommendations to improved quality of care. Eur Urol. 2023;83:402\u2013404. https:\/\/doi.org\/10.1016\/j.eururo.2023.01.011","DOI":"10.1016\/j.eururo.2023.01.011"},{"key":"113658","doi-asserted-by":"crossref","unstructured":"Stattin P. How to improve cancer care by use of guidelines and quality registers. Scand J Urol. 2024;59:190\u2013192. https:\/\/doi.org\/10.2340\/sju.v59.42272","DOI":"10.2340\/sju.v59.42272"},{"key":"113659","doi-asserted-by":"crossref","unstructured":"Stattin P, Sandin F, Sandback T, et al. Dashboard report on performance on select quality indicators to cancer care providers. Scand J Urol. 2016;50:21\u201328. https:\/\/doi.org\/10.3109\/21681805.2015.1063083","DOI":"10.3109\/21681805.2015.1063083"},{"key":"113660","doi-asserted-by":"crossref","unstructured":"Pathirana TI, Pickles K, Riikonen JM, et al. Including information on overdiagnosis in shared decision making: a review of prostate cancer screening decision aids. MDM Policy Pract. 2022;7:23814683221129875. https:\/\/doi.org\/10.1177\/23814683221129875","DOI":"10.1177\/23814683221129875"},{"key":"113661","doi-asserted-by":"crossref","unstructured":"Josefsson A, M\u00e5nsson M, Kohestani K, et al. Performance of 4Kscore as a reflex test to prostate-specific antigen in the GOTEBORG-2 pros-tate cancer screening trial. Eur Urol. 2024;86:223\u2013229. https:\/\/doi.org\/10.1016\/j.eururo.2024.04.037","DOI":"10.1016\/j.eururo.2024.04.037"},{"key":"113662","doi-asserted-by":"crossref","unstructured":"Auvinen A, Tammela TLJ, Mirtti T, et al. Prostate cancer screening with PSA, Kallikrein panel, and MRI: the ProScreen randomized trial. JAMA. 2024;331:1452\u20131459. https:\/\/doi.org\/10.1001\/jama.2024.3841","DOI":"10.1001\/jama.2024.3841"}],"container-title":["Scandinavian Journal of Urology"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/SJU\/article\/download\/43809\/50322","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/SJU\/article\/download\/43809\/50322","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T04:31:14Z","timestamp":1748925074000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/SJU\/article\/view\/43809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,3]]},"references-count":41,"URL":"https:\/\/doi.org\/10.2340\/sju.v60.43809","relation":{},"ISSN":["2168-1813"],"issn-type":[{"value":"2168-1813","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,3]]}}}